3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $812M | -$68M | 0.0% | 5.6% | $67M | $378M | $796M |
| 2024 | $412M | -$282M | 0.0% | -62.4% | -$254M | $373M | $64M |
| 2023 | $306M | -$341M | 0.0% | -104.4% | -$298M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $216M | -$510000 | 0.0% | 2.4% | $23M | $381M | $820M |
| Dec '25 | $293M | $82M | 0.0% | 30.2% | $40M | $378M | $796M |
| Sep '25 | $217M | $24M | 0.0% | 15.1% | $55M | $376M | $753M |
| Jun '25 | $181M | -$72M | 0.0% | -9.9% | — | $373M | $719M |
| Mar '25 | $121M | -$103M | 0.0% | -47.9% | -$34M | — | $31M |
| Dec '24 | $130M | -$37M | 0.0% | -28.5% | -$41M | $373M | $64M |
| Sep '24 | $102M | -$68M | 0.0% | -59.9% | -$71M | — | — |
| Jun '24 | $100M | -$66M | 0.0% | -67.0% | — | — | — |
How the market has priced CAI against its own fundamentals since 2025-06 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Caris Life Sciences, Inc.'s revenue has grown 62.9% per year. These are computed facts, not advice.
As of FY2025, Caris Life Sciences, Inc. reported $378M of total debt against $796M of cash; operating income covered interest expense 0.8×.
In FY2025, gross margin was —, operating margin 5.6%, and net margin -8.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.